CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 13 enrolled
Drug / intervention
MK-0941 +1 moredrug
Likely dose
MK-0941 140 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01106287
NCT01106287Phase 1Completed
CompareCT.gov

A Study of Higher Single Doses of MK-0941 in Type 2 Diabetics

Merck Sharp & Dohme LLC·interventional·Posted Apr 19, 2010·Updated Feb 4, 2016

In Brief

A Phase 1 clinical trial evaluating MK-0941 and Comparator: Placebo for Type 2 Diabetes. Completed, enrolled 13 participants.

Detailed Summary

This study will evaluate the safety and tolerability of single doses of MK-0941 based on assessment of clinical and laboratory adverse experiences

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 19, 2010
Enrollment StartOct 1, 2009
Primary CompletionJan 1, 2010
Study CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 16.2 years ago

Interventions

MK-0941drug

A single 60, 80, 100, 120 or 140 mg oral dose of MK-0941 will be administered in each period

Comparator: Placebodrug

a single oral placebo will be administered in the designated period (Periods 1-5)